Characteristic | Â | Absolute value | Â |
---|---|---|---|
Number of participants | Â | 61 | Â |
Number of male participants, (%) | Â | 56 | (92%) |
Age (y), median [IQR] | Â | 43 | [35-48] |
Route of transmission, (%) | Â | Â | Â |
 | homosexual | 46 | (76%) |
 | heterosexual | 13 | (21%) |
 | blood products | 2 | (3%) |
Nationality, (%) | Â | Â | Â |
 | Japanese | 61 | (100%) |
Nadir CD4 cell count (/μl), median [IQR]* |  | 175 | [54-256] |
Pre-ART VL (copies/ml), median [IQR]* | Â | 85500 | [41500-322500] |
Current CD4 cell count (/μl), median [IQR] |  | 569 | [442-818] |
Current ART regimen, no. (%) | Â | Â | Â |
 | PI-based | 32 | (52%) |
 | NNRTI-based | 25 | (41%) |
 | 3-NRTI | 4 | (7%) |
Duration of VL suppression (days), median [IQR] | Â | 2205 | [784-2737] |